{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:41:44Z","timestamp":1791333704320,"version":"4.3.1"},"reference-count":59,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["220026"],"award-info":[{"award-number":["220026"]}],"id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Research Council of Finland\u2019s Flagship InFLAMES","award":["337530"],"award-info":[{"award-number":["337530"]}]},{"name":"the Research Council of Finland\u2019s Flagship InFLAMES","award":["357910"],"award-info":[{"award-number":["357910"]}]},{"name":"the Research Council of Finland\u2019s Flagship InFLAMES","award":["358823"],"award-info":[{"award-number":["358823"]}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["330902"],"award-info":[{"award-number":["330902"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011797","name":"Turun Yliopistollinen Keskussairaala","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RFA-2203-39281"],"award-info":[{"award-number":["RFA-2203-39281"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Serum glial fibrillary acidic protein (sGFAP) is a promising biomarker for multiple sclerosis (MS) disease progression. Elevated sGFAP levels are considered to reflect ongoing astrocyte-related pathology in the central nervous system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To study whether sGFAP levels associate with 18\u2009kDa translocator protein (TSPO) availability in MS brain. TSPO is a mitochondrial molecule that is expressed by activated microglia and astrocytes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Cross-sectional multimodal biomarker correlation study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We included 80 people with MS (66 relapsing-remitting and 14 progressive MS, 69% women), and 11 healthy control participants (73% women). sGFAP was measured using single molecule array (Simoa\u00ae) technology in combination with 3T magnetic resonance imaging and positron emission tomography (PET) using a TSPO-binding [\n                      <jats:sup>11<\/jats:sup>\n                      C]PK11195 radioligand.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      sGFAP was higher among people with progressive MS (median 122\u2009pg\/ml) compared to healthy controls (median 59\u2009pg\/ml,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0002) or participants with relapsing-remitting MS (median 77\u2009pg\/ml,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0056). Among people with MS, higher sGFAP associated with higher volume of chronic lesions with increased TSPO activity (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      \u2009=\u20090.36,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0011) and with thalamic TSPO activity (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      \u2009=\u20090.30,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0069), as well as with T1 and T2 lesion loads (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      \u2009=\u20090.38, 0.41,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0005, 0.0002, respectively). Smaller normal-appearing white matter (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      \u2009=\u2009\u22120.36,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0009), cortical gray matter, and thalamus volumes (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      \u2009=\u2009\u22120.39,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0003 for both) correlated with higher sGFAP. In regression analyses, the volume of TSPO-expressing lesions, together with age and MS disease-modifying treatment status, explained 27% of the variation in sGFAP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>sGFAP associates with adverse magnetic resonance imaging and PET imaging outcomes. The association between a high prevalence of TSPO-expressing white matter lesions and high sGFAP suggests that lesion-associated glial activity promotes MS progression partially via astrocyte-driven mechanisms. A combination of various soluble biomarkers and PET ligands for specific cell types may add to the understanding of progression-promoting cellular mechanisms in the brain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov NCT03134716, NCT03368677, NCT04126772, NCT04239820,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\">https:\/\/clinicaltrials.gov<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864251352998","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T06:09:04Z","timestamp":1753769344000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Serum glial fibrillary acid protein associates with TSPO-expressing lesions in multiple sclerosis brain"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4477-8175","authenticated-orcid":false,"given":"Tanja","family":"Sj\u00f6ros","sequence":"first","affiliation":[{"name":"Turku PET Centre, University of Turku, \u00c5bo Akademi University, Turku University Hospital, P.O. Box 52, Turku 20521, Finland"},{"name":"Clinical Neurosciences, University of Turku, Turku, Finland InFLAMES Research Flagship, University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"Saraste","sequence":"additional","affiliation":[{"name":"Turku PET Centre, University of Turku, \u00c5bo Akademi University, Turku University Hospital, Turku, Finland"},{"name":"Clinical Neurosciences, University of Turku, Turku, Finland"},{"name":"InFLAMES Research Flagship, University of Turku, Turku, Finland"},{"name":"Neurocenter, Turku University Hospital, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Matilainen","sequence":"additional","affiliation":[{"name":"Turku PET Centre, University of Turku, \u00c5bo Akademi University, Turku University Hospital, Turku, Finland"},{"name":"Clinical Neurosciences, University of Turku, Turku, Finland"},{"name":"InFLAMES Research Flagship, University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6695-5684","authenticated-orcid":false,"given":"Marjo","family":"Nylund","sequence":"additional","affiliation":[{"name":"Turku PET Centre, University of Turku, \u00c5bo Akademi University, Turku University Hospital, Turku, Finland"},{"name":"Clinical Neurosciences, University of Turku, Turku, Finland"},{"name":"InFLAMES Research Flagship, University of Turku, Turku, Finland"},{"name":"Neurocenter, Turku University Hospital, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Koivum\u00e4ki","sequence":"additional","affiliation":[{"name":"Turku PET Centre, University of Turku, \u00c5bo Akademi University, Turku University Hospital, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-8892","authenticated-orcid":false,"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Departments of Biomedicine and Clinical Research, Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Leppert","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Departments of Biomedicine and Clinical Research, Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9751-5881","authenticated-orcid":false,"given":"Laura","family":"Airas","sequence":"additional","affiliation":[{"name":"Turku PET Centre, University of Turku, \u00c5bo Akademi University, Turku University Hospital, Turku, Finland"},{"name":"Clinical Neurosciences, University of Turku, Turku, Finland"},{"name":"InFLAMES Research Flagship, University of Turku, Turku, Finland"},{"name":"Neurocenter, Turku University Hospital, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00616-3"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.5250"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200052"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27034"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww298"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-009-0619-8"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00217"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/glia.22443"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518819380"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102810"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12389-y"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52187"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz287"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/1073858418783959"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-020-00221-2"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature21029"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200133"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa275"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001182"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx228"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awu331"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000574"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51431"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410130302"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1032"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20703"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22366"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-331051"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab301"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.131698"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000443"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2010.64"},{"key":"e_1_3_4_36_2","first-page":"158","article-title":"Reference and target region modeling of [11C]-(R)-PK11195 brain studies","volume":"48","author":"Turkheimer FE","year":"2007","unstructured":"Turkheimer FE, Edison P, Pavese N, et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med 2007; 48: 158\u2013167.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2012.59"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05309-z"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000691"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.26946"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae013"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67934-2"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2015.00180"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052130"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-025-03343-4"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1653-y"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03892-7"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26657"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211010082"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12239"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12299-z"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25150"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200299"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517726382"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25743"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.23144"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.575611"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516681504"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005201"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1191\/1352458505ms1140oa"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251352998","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251352998","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251352998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:05:20Z","timestamp":1767675920000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251352998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":59,"alternative-id":["10.1177\/17562864251352998"],"URL":"https:\/\/doi.org\/10.1177\/17562864251352998","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"article-number":"17562864251352998"}}